These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26321720)

  • 1. [A Newly Diagnosed Case of Multiple Myeloma in Which Lenalidomide Was Continued after Surgery for a Pancreatic Neuroendocrine Tumor That Developed during Lenalidomide Maintenance Therapy].
    Kuroda H; Yoshida M; Usami M; Shimoyama S; Sakamoto H; Yamada M; Fujii S; Maeda M; Fujita M; Kanari Y; Sato T; Kato J
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):1009-12. PubMed ID: 26321720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
    Usnarska-Zubkiewicz L; Dębski J; Butrym A; Legieć W; Hus M; Dmoszyńska A; Stella-Hołowiecka B; Zaucha JM; Januszczyk J; Rymko M; Torosian T; Charliński G; Lech-Marańda E; Malenda A; Jurczyszyn A; Urbańska-Ryś H; Druzd-Sitek A; Błońska D; Urbanowicz A; Hołojda J; Pogrzeba J; Rzepecki P; Hałka J; Subocz E; Becht R; Zdziarska B; Dytfeld D; Nowicki A; Bołkun Ł; Kłoczko J; Knopińska-Posłuszny W; Zubkiewicz-Kucharska A; Kuliczkowski K
    Leuk Res; 2016 Jan; 40():90-9. PubMed ID: 26626207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
    Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
    Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
    Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].
    Kuroda H; Jomen W; Yoshida M; Usami M; Yamada M; Abe T; Sakurai T; Fujii S; Maeda M; Matsuno T; Sato M; Kanari Y; Kato J
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1179-82. PubMed ID: 25248908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How lenalidomide is changing the treatment of patients with multiple myeloma.
    Dimopoulos MA; Terpos E; Niesvizky R
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
    Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
    Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
    Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
    Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.
    Yamasaki S; Kohno K; Kadowaki M; Takase K; Okamura S
    Intern Med; 2015; 54(14):1711-5. PubMed ID: 26179523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
    Takamatsu H; Munemoto S; Murata R; Terasaki Y; Nakajima K; Nakao S
    Anticancer Res; 2013 Dec; 33(12):5681-5. PubMed ID: 24324117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.
    Fuchida SI; Sunami K; Matsumoto M; Okumura H; Murayama T; Miyamoto T; Otsuka E; Fujishima N; Izumi T; Tamaki S; Hiramatsu Y; Kuroda Y; Shimazaki C; Akashi K; Harada M;
    Int J Hematol; 2019 Jan; 109(1):107-114. PubMed ID: 30284685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
    Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
    Broijl A; Kersten MJ; Alemayehu WG; Levin MD; de Weerdt O; Vellenga E; Meijer E; Wittebol S; Tanis BC; Cornelisse PB; Stevens-Kroef M; Bos GM; Wijermans PW; Lokhorst H; Sonneveld P
    Haematologica; 2016 Apr; 101(4):e149-52. PubMed ID: 26659914
    [No Abstract]   [Full Text] [Related]  

  • 16. [Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient].
    Uchida T; Inoue M; Hua J; Hagihara M
    Rinsho Ketsueki; 2016 May; 57(5):613-7. PubMed ID: 27263787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
    Syed YY
    Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation].
    Miura S; Kuroda H; Yamada M; Sato K; Ameda S; Sakano H; Shibata T; Uemura N; Abe T; Fujii S; Maeda M; Kobune M; Kato J
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):689-693. PubMed ID: 28860442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
    Majer I; van de Wetering G; Polanyi Z; Krishna A; Gray E; Roy A
    Appl Health Econ Health Policy; 2017 Feb; 15(1):45-55. PubMed ID: 27550239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
    Brown RE; Stern S; Dhanasiri S; Schey S
    Eur J Health Econ; 2013 Jun; 14(3):507-14. PubMed ID: 22572968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.